MARKET

NEO

NEO

Neogenomics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.82
+0.05
+0.58%
Opening 13:35 05/25 EDT
OPEN
7.78
PREV CLOSE
7.77
HIGH
7.99
LOW
7.66
VOLUME
533.37K
TURNOVER
2.16M
52 WEEK HIGH
54.74
52 WEEK LOW
7.26
MARKET CAP
974.99M
P/E (TTM)
-23.8117
1D
5D
1M
3M
1Y
5Y
NeoGenomics names interim CEO
NeoGenomics (NASDAQ:NEO) appointed Lynn Tetrault, Esq., current Executive Chair and Principal Executive Officer, as board chair and interim CEO, effective May 12. Ms. Tetrault has been serving as Executive Chair since March
Seekingalpha · 05/16 11:32
NeoGenomics Appoints Lynn Tetrault Interim CEO
MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq.
ACCESSWIRE · 05/16 11:00
NeoGenomics Appoints Lynn Tetrault as Interim CEO and Board Chair
MT Newswires · 05/16 07:56
NeoGenomics Appoints Vishal Sikri as President
MT Newswires · 05/11 17:23
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ...
ACCESSWIRE · 05/10 06:00
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial...
ACCESSWIRE · 05/09 11:00
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
FT MYERS, FL / ACCESSWIRE / May 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in investor...
ACCESSWIRE · 05/05 20:05
Investors in NeoGenomics (NASDAQ:NEO) have unfortunately lost 76% over the last year
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
Simply Wall St. · 05/05 10:53
More
No Data
Learn about the latest financial forecast of NEO. Analyze the recent business situations of Neogenomics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
50.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NEO stock price target is 18.82 with a high estimate of 26.00 and a low estimate of 12.00.
High26.00
Average18.82
Low12.00
Current 7.81
EPS
Actual
Estimate
-0.19-0.14-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 417
Institutional Holdings: 126.38M
% Owned: 101.30%
Shares Outstanding: 124.76M
TypeInstitutionsShares
Increased
86
6.13M
New
46
4.98M
Decreased
94
12.72M
Sold Out
69
4.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.70%
Healthcare Providers & Services
-0.14%
Key Executives
Chairman/Chief Executive Officer/Director
Lynn Tetrault
Chief Financial Officer
William Bonello
Corporate Executive
Clive Morris
Corporate Executive
David Sholehvar
Corporate Executive
Gina Wallar
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Marketing Officer
Marcus Silva
Chief Risk Officer
Kathryn Mckenzie
Other/IR Contact Officer
Douglas Brown
Other
Jennifer Balliet
Independent Director
Bruce Crowther
Independent Director
David Daly
Independent Director
Alison Hannah
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
Independent Director
Rachel Stahler
No Data
No Data
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.